Assembly Biosciences is a clinical-stage biotechnology company developing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus infection. Vebicorvir (VBR), Co.'s key inhibitor product candidate, is licensed from Indiana University. Co.'s second-generation key inhibitor product candidate, ABI-H2158 (2158), was internally discovered and developed and is chemically distinct from VBR. Co.'s third key inhibitor product candidate, ABI-H3733 has a chemical scaffold separate from VBR and 2158. In addition to its three clinical-stage product candidates, Co.'s research discovery team is focused on identifying and selecting a fourth-generation key inhibitor candidate. The ASMB stock yearly return is shown above.
The yearly return on the ASMB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ASMB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|